Announcements Trials

Browse Landscape

Phase

Status

Terminated 1 No longer available 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 8 Neoplasms 2 Recurrence 1 Ovarian Neoplasms 1 Oligodendroglioma 1 Neuroblastoma 1 Neoplasm Metastasis 1 Granulosa Cell Tumor 1 Glioma 1 Glioblastoma 1 Genetic Diseases, Inborn 1 Castration-resistant Prostate Cancer 1 Brain Neoplasms 1 Astrocytoma 1

Interventions

Cyclophosphamide 6 Isotretinoin 5 thymoglobulin 4 fludarabine phosphate 4 fludarabine 4 aldesleukin 4 Topotecan 4 Temozolomide 4 Melphalan 4 Irinotecan 4 Etoposide 4 ribociclib 3 Thiotepa 3 Interleukin-2 3 Granulocyte Colony-Stimulating Factor 3 Filgrastim 3 Busulfan 3 Bone Marrow Transplantation 3 Antilymphocyte Serum 3 temsirolimus 2 omburtamab I-131 2 dinutuximab 2 Vincristine 2 Tretinoin 2 TPI-287 2 Stem Cell Transplantation 2 Rituximab 2 Radiotherapy 2 Peripheral Blood Stem Cell Transplantation 2 Nivolumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Neuroblastoma × Ketoconazole × Clear all

NCT02163356 2022-03-31

SPOC2013-001

South Plains Oncology Consortium

Phase 1 Terminated

Neuroblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡